



OmniAb, Inc.

Nasdaq: OABI

May 2024



Disclaimer

We caution you that this presentation contains forward-looking statements.

All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected operating expense and cash runway, business strategy, our expectations regarding the application of, and the rate and degree of market acceptance of, our technology platform and other technologies, our expectations regarding the addressable markets for our technologies, including the growth rate of the markets in which we operate and the need for antibody-related discovery technologies, the staffing and resources required, and our ability to leverage the growth of our business, the timing of the initiation or completion of preclinical studies and clinical trials by our partners, expectations regarding product approvals and potential for future revenue growth, launches by our partners and the timing thereof, the anticipated introduction of new technologies and innovations and enhancement of our technology stack and partners' experiences, the continued innovation around and the expected performance of our technologies and the opportunities they may create, the ability to add new partners and programs, and the potential for and timing of receipt of milestones and royalties under our license agreements with partners, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain, risks arising from changes in technology; the competitive environment in the life sciences and biotechnology platform market; our failure to maintain, protect and defend our intellectual property rights; difficulties with performance of third parties we will rely on for our business; regulatory developments in the United States and foreign countries; unstable market and economic conditions, may have serious adverse consequences on our business, financial condition and stock price; we may use our capital resources sooner than we expect; and other risks described in our press releases and filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Information regarding partnered products and programs comes from information publicly released by our partners.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about the antibody industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Our Business

LEVERAGING OUR PROPRIETARY DISCOVERY TECHNOLOGY PLATFORM WORLDWIDE



Technology Offering Addresses Most Critical Challenges of Discovery

Create, Screen, Deliver antibodies leveraging industry's only 4-species platform with differentiated tech and core competencies

**POISED FOR
GROWTH
TO MEET A
GLOBAL
INDUSTRY
NEED**

One of the Largest Greenfields in the Pharma Industry



Total addressable market for antibodies expected to surpass \$300 billion in 2027



Leading, Proven and Leveragable Technology

Growing numbers of partners and programs

Innovation and Intelligent Expansion of Our Technology



New technology launches and an increasingly efficient internal technology innovation engine

Sources: Clarivate Analytics Cortellis database.

Mission

Our mission is to enable the rapid development of innovative therapeutics by **pushing the frontiers of drug discovery technologies.**

Demand for Discovery Technology is Increasing

Higher industry success rates and other factors are driving an acceleration of antibody-based investment by the pharmaceutical industry

Higher Success Rates
vs.
Small Molecules

Historical overall success rates for antibodies have been significantly higher than for small molecules.⁽¹⁾

Inflation Reduction
Act (IRA)

**Provision for drug price negotiations
between Medicare and drug makers**


Small molecule drugs are eligible for negotiation 7 years after approval while large molecule are not eligible until 11 years after approval.

In a PhRMA survey of biopharmaceutical companies, 63% said they expect to shift R&D investment away from small molecule medicines as a result of the IRA.⁽²⁾

Data from *The Antibody Society* suggests the industry is further improving clinical success rates for antibodies

Phase 1 to Any Approval - Success Rates over Time³

Phase Transition and Approval Success Rates
(for antibody therapeutics which entered clinical studies 2000 – 2019)



Final outcomes (approval or termination) known for 90%, 84%, and 59% of molecules for 2000-2009, 2005-2014, 2010-2019 periods, respectively.

(1) BIO | QLS Advisors | Informa Feb 2021 Report; Applied Clinical Trials

(2) phrma.org; <https://phrma.org/en/Blog/WTAS-Inflation-Reduction-Act-already-impacting-RD-decisions>

(3) Trends in Commercial Development of Antibody Therapeutics, The Antibody Society, Inc., October 24, 2023; <https://www.antibodysociety.org/learningcenter/antibodies-to-watch-webinar-series/>.

Q1 2024 Highlights

POSITIONING THE BUSINESS FOR FUTURE GROWTH



Continuing to **grow and diversify** our partnership base




An expanded presence is **creating greater visibility**
for our technology with target audience



Newest innovations and workflows **driving value**
for stakeholders

Active Partners

Q1 2024: 80 ACTIVE PARTNERS




- 3 new platform license agreements were signed in the first quarter
 - New platform license agreements with a stealth Boston-based venture-backed start-up, ImmunoBiochem Corporation, and the University of Georgia
- Near doubling of active partners since 2018, net of attrition

Represents the unique number of partners that have an active program or have executed a license agreement in advance of initiating an active program.

Active Programs

GROWTH AND PROGRESSION CONTINUES




- Number of Active Programs increased to 327, net of attrition
- 3 programs successfully transitioned from **Discovery** to **Preclinical**, 1 program from **Phase 1** to **Phase 2**

Represents programs for which research work has commenced or an antigen is introduced into our animals and remains so as long as the program is actively being developed or commercialized. Reported numbers above are net of attrition, as of 3/31/2024. Preclinical stage programs are programs that are confirmed to be in pre-IND studies by partners. GEN1047 is in a Phase 1/2 study, partner (Genmab) now categorizes as a Phase 2 program.

Active Clinical Programs and Approved Products

Number of
Active Clinical Programs
and Approved Products



- 31 active clinical programs as of 3/31/2024
 - RO7515629/RG6353⁽¹⁾, a Phase 1 antibody program in oncology removed following a "portfolio shaping" initiative at Roche⁽²⁾
- Based on dialogue with partners, we continue to see potential for approximately 4 - 6 new entries into clinical development for novel OmniAb-derived antibodies in 2024, with programs addressing major unmet medical needs

(1) Roche/Genentech program (RO7515629/RG6353) was subject of a pre-paid license, per a 2013 agreement with OMT, Inc.

(2) Reference Roche public disclosures and Clinicaltrials.gov (NCT05769959 study terminated in March 2024, citing "sponsor decision not related to safety, efficacy or quality")

Select OmniAb Partners

>75 COMPANIES CURRENTLY HAVE ACCESS TO OMNIAB ANTIBODIES



2024: Looking Ahead To Continued Progress

PIPELINE GROWTH AND ADVANCEMENT, NEW DEALS AND TECHNOLOGY DEPLOYMENT



Late-stage advancement and data events expected for key clinical programs at Genmab, Immunovant and others⁽¹⁾



Leverage fully-staffed business development team for deal expansion globally



Continue to focus on innovation, expansion of the technology platform and introduction of new technology and partner experience enhancements

(1) Genmab/BioNTech: Acasunlimab - Genmab plans to initiate a Phase 3 study of acasunlimab in a second-line non-small cell lung cancer indication in 2024. Immunovant/Hanall Biopharma: Batoclimab – Immunovant expects Phase 2b data in chronic inflammatory demyelinating polyneuropathy in 2Q or 3Q 2024 and Phase 3 topline data in Myasthenia gravis in 2H24, IMVT-1402 - Immunovant announced plans to initiate new potentially registrational programs for IMVT-1402.

Select Partner Updates

RECENT DEVELOPMENTS AND UPCOMING KEY EVENTS



Batoclimab

FcRn

Immunovant reported that global Phase 3 clinical trials of batoclimab in myasthenia gravis (MG) and thyroid eye disease (TED) are progressing and on track for topline data in the second half of 2024 (MG) and the first half of 2025 (TED).

Initial period 1 data from Phase 2b clinical trial of batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) are expected in the second or third quarter of 2024.

HanAll and Immunovant are progressing a Phase 3 clinical study in generalized myasthenia gravis in Japan. Clinical trial notification was approved to initiate a Phase 3 clinical study of batoclimab in TED in Japan.



IMVT-1402

FcRn

Immunovant announced plans to initiate 4 - 5 potentially registrational programs for IMVT-1402 over next fiscal year; and also plans on initiating trials in 10 indications for IMVT-1402 over the next two fiscal years.

Immunovant announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,926,669 for IMVT-1402; allowed claims cover composition of matter for the binding sequence of IMVT-1402 to FcRn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. Not including any potential patent term extension, patent will expire on June 23, 2043.



M9140

CEACAM-5 ADC

AACR presentation on M9140, a novel antibody-drug conjugate with topoisomerase 1 inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing tumors.

M9140 demonstrated high potency, strong antitumor activity, and bystander effect in preclinical efficacy models.

A first-in-human Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in patients with advanced solid tumors is ongoing (NCT05464030).



Acasunlimab

PD-L1 x 4-1BB

Genmab expects acasunlimab (formerly GEN1046) Phase 2 data in second-line non-small cell lung cancer (NSCLC) in the first half of 2024.

Genmab plans to initiate a Phase 3 study of acasunlimab in second-line NSCLC in 2024.


Upcoming Scientific Presentations

INCREASING THE VISIBILITY OF OUR TECHNOLOGY PLATFORM



May 15th
Boston

Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery
Bob Chen, Ph.D.



**Antibody Engineering
& Therapeutics
Europe**



June 4th
London

OmniAb™: Transgenic Chickens Producing Human Heavy Chain-Only Antibodies Demonstrate Robust Immune Repertoires and High-Affinity Binding
Christine Vuong, Ph.D.



June 12th

OmniAb Webinar Series

Advanced Antigen Design Strategies for Shaping Human Antibody Repertoires in OmniAb Animals
Devendra Srivastava, Ph.D.




June 27th
South Korea

Reimagining ADCs with OmniAb's Next-Generation Therapeutic Antibody and Alternative Scaffold Technologies
Yasmina Abdiche, Ph.D.

The OmniAb Technology Offering Continues to Expand

TECHNOLOGY OFFERING ADDRESSES THE MOST CRITICAL CHALLENGES OF ANTIBODY DISCOVERY




*OmniAb entered into an agreement with mAbsolve Ltd. for STR, mAbsolve's Fc-silencing platform technology, which provides OmniAb with exclusive, sublicensable right to incorporate the STR technology with antibodies that have been generated using OmniAb's antibody discovery platform.

What is *Biological Intelligence*™?

- We believe that antibodies generated *in vivo* are superior to ones from other sources because they are **naturally optimized** through an iterative process that preferentially selects for antibodies with excellent specificity and developability profiles
- The ability of the immune system in our engineered transgenic animals to create optimized antibodies for human therapeutics is what we call ***Biological Intelligence***
- We believe this approach **increases the efficiency and probability of success** of therapeutic antibody discovery and may help limit the attrition of antibody product candidates in the clinic

Some Differentiating Features of our Technology

			
OmniChicken[™] OmniClic[®] OmniAb[™]	OmniRat[™] OmniFlic[™]	OmniTaur[™]	xPloration[®]
• Evolutionary distance advantage vs. mammals • Broad epitope coverage on a wide-range of targets	• Rat species difference from mice, with similar ease-of-use • B-cell quantity advantage vs. mice • Approved antibodies, US/EU/Asia	• Ultra-long CDRs enable targeting ion channel interiors and other epitopes thought of as physically inaccessible to antibodies • CDRs cleavable into picobody[™] knobs	• High throughput B-cell screening platform; 1.5M simultaneously • Integrated AI and sequencing to maximize repertoire mining

Our platform is attracting new partners and enables our existing partners to expand use

The OmniAb Platform


Create

Screen

Deliver

17

Antibody Generation Technologies



Computational
Antigen Design &
Proprietary Reagents

OmniRat[™] OmniChicken[™] OmniMouse[™]

Robust Antibodies for Any Target

OmniFlic[™] OmniClic[™]

Bispecific Antibody
Generation

OmniAb[™] OmniTaur[™]

Novel Scaffolds

We believe generating **large and diverse** repertoires of high-quality antibodies increases the likelihood of **discovering the antibody** with the **most desirable therapeutic characteristics**

Industry's only 4-species platform

*3 approved and increasing number
of clinical-stage antibodies*

A rich heritage of genetic engineering advancements


Carefully designed transgenes for robust response

*Bispecific and cow-inspired technologies
enable next-generation therapeutics*

Rodent Platforms




- Endogenous Ig genes inactivated
- Expression of full human V gene diversity
- Streamlined conversion into fully human molecule



Well-validated transgene design utilizes rodent constant regions for robust immune responses from the B-cell repertoire

Our Chicken Platforms - Powered by Evolution

GREATER EVOLUTIONARY DISTANCE YIELDS
GREATER IMMUNOGENICITY AND MORE ANTIBODY DIVERSITY




Common Light Chain Platforms for Bispecific Antibodies

STANDARD IgG FORMAT TO DE-RISK DOWNSTREAM DEVELOPMENT[†]




Rearranged
IgVK3-15/JK1



Fixed human VK3-15 light chain expressed with diversifying heavy chain from *any* human germline (44 VHs)




IgVK3-15/JK1




Fixed human VK3-15 light chain combined with diversifying heavy chain on single scaffold (VH3-23) for superior developability

OmniFlic® & OmniClic® enable IgG-like asymmetric formats

Target A




Target B



+



Facile reformatting via Knob-in-Hole or other Fc-mutations that drive Fc heterodimerization




Classical IgG-like format*

Bispecific

[†]Gera, Nimish. "The evolution of bispecific antibodies." *Expert Opinion on Biological Therapy* (2022)

Omni^dAb™



Omni^dAb is the first and only transgenic chicken producing single domain antibodies (sdAb), a novel class of antibody found naturally in camelids that is being increasingly exploited for a variety of therapeutic applications.

Omni^dAb is an *in vivo* platform for sdAbs based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems.

What's driving interest in Omni^dAb?

*"we are looking to deliver payloads **deep into solid tumors**"*

*"we are building a **panel of multispecific molecules** based on tethered sdAbs"*

*"transporting across the **blood brain barrier** via a highly conserved receptor"*

*"looking for sdAb immune cell engager that can be **linked** to a variety of targeting molecules"*


*"rapid generation of **high affinity human sequence** sdAb candidate molecules"*

What is a Single-Domain Antibody (sdAb)?

ALSO KNOWN AS VHH ANTIBODIES OR NANOBOBODIES®

Conventional antibody (IgG)

Comprised of 2 heavy chains and 2 light chains



Total MW ~150kD
Binding domain is VH x VL

sdAb


VH domain of HcAb can be expressed independently as an autonomous sdAb unit



**Compact format of sdAb (~15kD)
opens new and important opportunities**

Heavy chain-only antibody (HcAb)

Found naturally in camelids, comprised of 2 heavy chains, no light chain



Total MW ~100kD
Binding domain is VH only

Opportunities for sdAbs in Medicine

PHYSICAL PROPERTIES CAN BE LEVERAGED FOR IMPORTANT APPLICATIONS



Alternate routes of administration

Injectable, inhalable & oral



Penetration + fast/tunable clearance

Blood-brain barrier, tissue, tumor




Imaging/diagnostics/theranostics

Small size compatible with PET/CT imaging radiolabels




Broad therapeutic applications

*Central nervous system and neurodegenerative diseases
Infectious and Autoimmune diseases
Cancer (especially bi/multi-specifics & CAR-T)*




OmniTaur: Ultralong CDRH3 Create Novel Binding Domains

UNIQUE STRUCTURAL FEATURES OF ULTRALONG H3 ANTIBODIES



- Novel structure may enable targeting epitopes unreachable by standard antibodies
- Long H3 domains can be expressed on human VH framework, or alone as ~5kD Picobodies™



Stanfield et al. *Sci Adv* 2020


Antibody Repertoires

NUMEROUS OPTIONS AVAILABLE TO ADDRESS DIVERSE PARTNER OBJECTIVES

Host	V genes	Structural and immunological features	Benefits for therapeutics discovery and development
 OmniMouse™	• Full human V gene diversity • Choice of light chain isotype	• Diverse V gene usage and mixed genetic backgrounds	• Widely accessible and flexible workflows
 OmniRat™	• Full human V gene diversity • Choice of light chain isotype	• Diverse V gene usage and mixed genetic backgrounds • Distinctive target recognition	• Industry standard • Widely accessible and flexible workflows • Extensive clinical track record
OmniChicken™	• Single framework • VH3/VK3 or VH3/VL1	• Evolutionarily divergent host system for robust immune responses	• Diverse and new epitope coverage • High homology targets • Excellent physical properties
 OmniFlic™	• Full human VH gene diversity with non-diversifying VK3	• Fixed light chain for bispecific applications • Distinctive target recognition	• Bispecific applications leveraging standard IgG format
OmniClic™	• Single framework • VH3/non-diversifying VK3	• Fixed light chain for bispecific applications	• Diverse epitope coverage • Excellent physical properties • Ease of manufacturing
OmniAb™	• Single domain human framework, human VH3-23	• Compact scaffold and binding paratope opens new and important opportunities	• Diverse epitope coverage • Unique modalities (NANOBODIES®) • Building Blocks for bi-, multi- specifics and CAR-T
 OmniTaur™	• Single framework • VH4/VL1	• Ultralong CDR-H3's for enormous structural diversity	• Access cryptic epitopes • Unique modalities (Picobodies™) • Building blocks for multispecific molecules

Screening Platforms

26



Our powerful single B-cell screening technologies, ***xPloration***[®] and **GEM assay**, **bypass bottlenecks of hybridoma workflows**

AI-driven multi-parameter screening of **tens of millions** of cells in **hours instead of weeks**

Technologies enable **screening against difficult targets**: GPCRs, ion channels and surface antigens

The OmniAb Platform

Create




Screen

Deliver

27


Our discovery teams are flexibly positioned to work closely with partners to identify the right antibody

- Data from multi-parameter screening and performance assays used in combination with bioinformatics
- NGS hit expansion to identify variant antibodies with improved characteristics
- High-throughput epitope binning and kinetics analysis, and target-specific functional assays
- Proprietary assays for ion channel and transporter targets



OmniDeep™ Streamlines and Assists Drug Discovery

OmniDeep is a suite of *in silico* tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities




OmniDeep™

Studies and embeds *Biological Intelligence*™ into AI and machine learning to assist discovery and optimization


Offers partners new large-scale discovery workflows and optimization tools for existing discovery campaigns

Provides the best of our *in vivo* and *in silico* capabilities



Ion Channels and Transporters

- Ion channels are proteins that allow ions, which are charged atoms/molecules, to flow into and out of cells across cell membranes resulting in very small electrical currents
- Present in all human cells and affect vital functions such as nerve transmission, muscle contraction, cellular secretory processes and fluid movement
- Have broad therapeutic applicability including neurologic and metabolic diseases, pain, cancers, infectious diseases, and many others



In the search for novel drugs, ion channels are viewed as high-value targets

Ion Channels and Transporters

DIFFERENTIATED DISCOVERY PLATFORM AT OMNIAB

- One of industry's most experienced teams of ion channel drug discovery experts - with decades of experience in small molecules, now being leveraged to advance antibody targeting of ion channels
 - Rich heritage of scientific *"firsts"* in the ion channel space, especially in neuro and pain therapy areas⁽¹⁾
- Continuous expansion and development of cutting-edge technologies including custom cell lines, high-throughput electrophysiology, proprietary X-ray fluorescence, structure-based optimization leveraging cryo-EM and molecular dynamics, deep learning models, etc.



Discovery-Stage Collaborations for
High-Value Targets with
Global Big Pharma Partners

GSK

**Neurological
Diseases**



**Neurodevelopmental
&
Neurodegenerative
Diseases**

(1) References: Jarvis, et al, PNAS vol. 104, no. 20, 2007 "A-803467, a potent and selective Na_v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in rat"; and Lin, et al, PLOS One, 1371, 2016 "Biophysical and pharmacological characterization of Na_v1.9 voltage dependent sodium channels stably expressed in HEK-293 cells."

Intellectual Property Advantage


PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL

Over 300 patents issued worldwide

- We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our technology platform
- Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a lengthy coverage tail

~90 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2043

**Antibody Patent Applications
Filed by Partners**



Business Model


OUR AGREEMENTS ARE STRUCTURED TO ALIGN ECONOMIC AND SCIENTIFIC INTERESTS WITH OUR PARTNERS

License partnerships designed to include:


- *Upfront/Access fees*
- *Potential Collaboration/Service revenue*
- *Milestones*
- *Royalties on commercial sales*

Illustrative Antibody Deal Structure

Profile A



Profile B



Notes: Deal Economics have evolved over time. Unique deal structures may also be used (e.g., equity stakes, risk-sharing, buy-in options, etc.).
Not representative of *Icagen Ion Channel Technology* deal structures.

Q1 2024 vs. Q1 2023 Financial Results

(Millions, except per share data)

	Q1 2024	Q1 2023	Variance
License and milestone revenue	\$ 0.7	\$ 12.6	(\$ 11.9)
Service revenue	2.8	4.0	(1.2)
Royalty revenue	0.3	0.3	0.0
Total revenues	3.8	16.9	(13.1)
Research & development	14.6	13.8	0.8
General & administrative	8.3	8.2	0.1
Amortization of intangibles	3.4	3.4	0.0
Other operating (income) expense, net	0.1	0.0	0.0
Total operating expenses	26.4	25.4	1.0
Income (loss) from operations	(22.6)	(8.5)	(14.1)
Other income (expense)	1.0	1.3	(0.3)
Loss before income taxes	(21.6)	(7.1)	(14.4)
Income tax (expense) benefit	2.6	1.0	1.6
Net Income (loss)	(\$ 19.0)	(\$ 6.1)	(\$ 12.9)
Net loss per share, basic and diluted	\$ (0.19)	\$ (0.06)	
Shares used in diluted per share calculation	100.8	99.2	

The Company expects operating expense in 2024 to be approximately the same as in 2023, and is now staffed and resourced to leverage the future growth of the business

Table includes rounded figures. Please reference press release dated 5/9/2024 for more detailed information.

Balance Sheet

(Millions)

	March 31, 2024	December 31, 2023
ASSETS		
Current assets:		
Cash & investments	\$ 69.0	\$ 87.0
Accounts receivable, net	4.0	3.8
Other current assets	3.7	4.1
Goodwill & intangible assets	236.0	239.4
PPE & leases	37.3	38.2
Other assets	2.5	2.7
Total assets	\$ 352.5	\$ 375.2
LIABILITIES AND STOCKHOLDERS' EQUITY		
A/P & accrued exp	\$ 7.6	\$ 11.4
Contingent liabilities	4.1	4.5
Deferred revenue	5.8	7.7
Operating lease liabilities	24.9	25.6
Deferred income taxes, net	8.7	11.4
Stockholders' equity:	301.4	314.6
Total liabilities and stockholders' equity	\$ 352.5	\$ 375.2

We expect cash use in 2024 to be relatively similar to the cash use in 2023, excluding the \$35M TECVAYLI[®] milestone that was received in Q1 2023

Given the expected progression of our existing partnered pipeline, we expect the cash use in 2025 to be substantially lower than in 2024

Our current cash balance and cash from operations are expected to provide sufficient capital to fund operations for the foreseeable future

Table includes rounded figures. Please reference press release dated 5/9/2024 for more detailed information.

Share Information – as of 03/31/24

(in millions)

Basic Share Count	101.1
Total Earnout Shares	16.3
RSU/Options/Warrants	
Employee Unvested RSU/PSU	2.4
Employee Options	22.4
Public Warrants	7.7
Private Warrants	11.3
Total RSU/Options/Warrants	43.9
Total Potential Shares	161.3

- Basic Shares
 - Common Shares Outstanding/Public Float
- Earnout Shares
 - 50% vest at \$12.50, 50% vest at \$15.00
 - VWAP of stock for 20 out of 30 consecutive trading days at each respective level for vesting to occur
 - Expire 11/1/27
- Warrants
 - Expire 11/1/27, \$11.50 strike price

Our Key Areas of Focus

WE BELIEVE WE ARE WELL-POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY AND GLOBAL HUMAN HEALTH

We leverage a **highly scalable business** where investments in technologies and innovation are informed by discovery relationships with our partners



Partnered Pipeline
Development,
Expansion and
Advancement



Continued Workflow
Versatility Initiatives



Expanding the
Reach of our
Platform



New Technology
Development and
Launches

WE FOCUS ON KEY STAKEHOLDERS



Team

Strong culture -
develop, motivate the best



Partners

Focus on customer
service and future needs



Investors

Superior business
execution to create value



Community

Lead with integrity
and responsibility



For more information, please visit www.omniab.com

Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 3/31/2024

40

Partner	Program	Source Animal	Therapy Area	Target	Phase 1	Phase 2	Phase 3	Registration	Approved
  	Zimberelimab	OmniRat	Oncology	PD-1					
 	Sugemalimab	OmniRat	Oncology	PD-L1					
	Teclistamab	OmniRat	Oncology	BCMA x CD3					
  	Batoclimab	OmniRat	Immunology	FcRn					
	Tiragolumab	OmniRat	Oncology	TIGIT					
 	Acasunlimab	OmniRat	Oncology	PD-L1 x 4-1BB					
	M6223	OmniRat	Oncology	TIGIT					
	GEN1047	OmniRat	Oncology	B7H4 x CD3					
	JNJ-70218902	OmniRat	Oncology	TMEFF2 x CD3					
	JNJ-78306358	OmniRat	Oncology	HLA-G x CD3					
	APVO436	OmniMouse	Oncology	CD123 x CD3					
	TQB2223	OmniRat	Oncology	LAG-3					
	S095018	OmniRat	Oncology	TIM-3					
	S095024	OmniRat	Oncology	CD73					
	S095029	OmniRat	Oncology	NKG2A					
	ABBV-383	OmniFlic	Oncology	BCMA x CD3					
	AZD0486	OmniFlic	Oncology	CD19 x CD3					
	AMG 340	OmniFlic	Oncology	PSMA x CD3					
	SAL003	OmniRat	Metabolic	PCSK9					
	Undisclosed	OmniRat	Oncology	Undisclosed					
	CN1	OmniRat	Oncology	Undisclosed					
	Undisclosed	OmniChicken	Oncology	CD137 x FAP					
	TEV-53408	OmniRat	Gastrointestinal	IL-15					
	M9140	OmniRat	Oncology	CEACAM-5					
 	GEN1053	OmniRat	Oncology	CD27					
	JNJ-79635322	OmniRat	Oncology	BCMA x GPRC5D x CD3					
	PF-08046049 (SGEN-BB228)	OmniRat	Oncology	CD228 x 4-1BB					
 	IMVT-1402	OmniRat	Immunology	FcRn					
	GLS-012	OmniRat	Oncology	LAG-3					
	CSX1004	OmniRat	Drug overdose	Fentanyl					
	BC3195	OmniRat	Oncology	CDH3					

Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020; OmnidAb 2023

Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with \$35M launch milestones paid. JNJ-78306358 is a Johnson & Johnson investigational bispecific therapy with completed Phase 1 study.

 Indicates program with fully paid license from OMT, Inc. prior to acquisition.

 Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. On October 31, 2023 Amgen announced plans to discontinue Phase 1 study of AMG 340 in mCRPC.